



Miami Thyroid Oncology Symposium

March 18-19, 2022

Virtual Event

Featured Workshop

Advances in Radioactive Iodine Theranostics

Symposium Overview



We welcome you to the 5th Annual Miami Thyroid Oncology Symposium to discuss the rapidly expanding science of “Molecular Theranostics”. Our approach to thyroid nodules and thyroid cancer has expanded beyond conventional diagnostics and therapeutic interventions. A broad catalogue of genomic and epigenomic markers associated with thyroid cancer is now available and are in clinical use. The risk stratification systems that are critical for initial surgical treatment and subsequent use of radioactive iodine treatment rely more and more on distinct molecular markers, and less on traditional parameters. Genomics with molecular pathology and molecular imaging reflect the true biologic nature of the different cancer types currently defined by conventional morphologic features. The tumor differentiation/de-differentiation and clinical behavior for each individual cancer are now being defined by molecular characteristics, in addition to standard histopathology.

The Miami Thyroid Oncology Symposium offers a platform for in depth discussions of the science of thyroid cancer diagnosis and treatment in this new paradigm. It is a unique scientific forum where practicing physicians learn how to adopt and incorporate the new diagnostic and treatment tools and techniques into their daily practice.

The symposium is a two-day program. The first day of the symposium on Friday March 18, 2022 will feature a workshop on ***Advances in Radioactive iodine (RAI) Theranostics***, which will provide in depth overview of RAI theranostics and address current controversies on RAI imaging, ablation and approaches for RAI-indifferent cancers. The plenary session on the second day of the symposium on Saturday, March 19, 2022 is entitled ***Frontiers in Thyroid Oncology***. This session brings together world renowned experts presenting and discussing the state of the art in Thyroid cancer diagnosis and treatment.

The 2022 Miami Thyroid Oncology Symposium (MTOS) will be held in a virtual format due to the unsettling course of the Covid19 pandemic. We are committed to uphold the high-quality symposium standards we have built in the prior years. We are indebted to our world-renowned faculty for taking part in this exciting new scientific platform. We also hope to expand our attendance by reaching to a larger national and international audience via the virtual format.

Seza Gulec

Seza Gulec, MD, FACS, FACNM
Symposium Director
MCRC President and Chairman of the Board



Symposium Faculty

Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Yuri E. Nikiforov, MD, PhD

Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

James A. Fagin, MD

Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

R. Michael Tuttle, MD

Chief, Endocrinology Service, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

Markus Luster, MD

Professor of Nuclear Medicine
Department of Nuclear Medicine, University Hospital Marburg, Germany

Luca Giovanella, MD

Professor of Nuclear Medicine, Clinic of Nuclear Medicine and Thyroid Centre
Imaging Institute of Southern Switzerland, Bellinzona, Switzerland

Maria Cabanillas, MD

Professor and the Faculty Director of Clinical Research
Department of Endocrine Neoplasia, MD Anderson, Houston, TX

Steven Larson, MD, FACNP

Hedvig Hricak Chair in Radiology; Attending, Molecular Imaging and Therapy Service,
Member and Lab Head, Molecular Pharmacology Program
Memorial Sloan Kettering Cancer Center

Bennett Greenspan, MD, FACNP

Chairman of Advisory Board and Senior Associate Researcher
Miami Cancer Research Center, Miami, FL

Douglas Van Nostrand, MD, FACP, FACNP

Director of Nuclear Medicine at MedStar Health Research Institute
Professor of Medicine at Georgetown University Medical Center in Washington, DC

Erivelto Volpi, MD

Department of Head and Neck Surgery, Oswaldo Cruz German Hospital
Professor in Head and Neck Surgery, CETRUS Medical School, Sao Paulo, Brasil

Atil Kargi, MD

Associate Professor of Medicine and Endocrinology
University of Miami Miller School of Medicine

Frederick Grant, MD

Department of Radiology, Children's Hospital of Philadelphia, Perelman School of Medicine
University of Pennsylvania, Philadelphia, PA

Nuclear Oncology Workshop
Advances in Radioactive Iodine Theranostics
Friday, March 18, 2022
07:30-12:00

07:30 Welcome and Introduction: **S. Gulec**

08:00-08:30 **Nuclear Medicine in the Evolving Paradigm of RAI Theranostics: F. Grant**
Changing concepts in RAI theranostics
Interdisciplinary communication and collaboration

08:30-09:00 **Physiologic and Molecular Basis of RAI Theranostics: S. Gulec**
Tumor Biology and RAI Physiology: Iodine Metabolism and RAI kinetics
MAPK and TDS
Theranostic and therapeutic power and performance

09:00-09:30 **Regulation of Differentiation State in Thyroid Cancer: J. Fagin**
ERK upstream and downstream substrates
ERK action on thyroid differentiation
Thyroid Differentiation Score

09:30-10:00 **Thyroglobulin: Biology, Physiology and Clinical Meaning: L. Giovannella**
Thyroglobulin physiology
Pitfalls and caveats in clinical testing
Diagnostic and Prognostic Value of Thyroglobulin


10:00-10:30 **Molecular Diagnostics and Theranostics: Y. Nikiforov**
Mutational landscape of malignant thyroid nodules
Gene expression alterations
Potential impact on RAI Theranostics

10:30-11:00 *Break and Exhibits*

11:00-11:30 **Radiobiology of I-131: M. Luster**
Safety of RAI Treatment
Safe cure with Curie: Facts and fiction
Deterministic and Stochastic effects


11:30-12:00 **Q/A**

12:00 *Lunch Break and Exhibits*



Nuclear Oncology WORKSHOP
Advances in Radioactive Iodine Theranostics
Friday, March 18, 2022
13:00-17:00

- 13:00-13:30 **Appropriate use of RAI in 2022: B. Greenspan**
Principles of RAI Ablation and Therapy
The RAI tradition and evolving theranostic paradigm
Impact of advances in molecular medicine in thyroid cancer management
- 13:30-14:00 **Refractory Thyroid Cancer : D. Van Nostrand**
Definitions and Classifications:
RAI Refractory Disease, RAI Resistant Disease, RAI Indifferent Cancer
- 14:00-14:30 **PET/CT Imaging in Thyroid Cancer: S. Larson**
FDG-PET/CT
I-124 PET/CT
F-18 TFB PET/CT
- 14:30-15:00 *Break and Exhibits*
- 15:00-15:30 **Post thyroidectomy RAI imaging and Ablation: S. Gulec**
Remnant anatomy for surgeons and nuclear medicine physicians
The theranostic performance of post-thyroidectomy imaging
- 15:30-16:00 **RAI Dosimetry: S. Larson**
Rationale and outcomes of Dosimetry
Clinical feasible Techniques
- 16:00-17:00 **Q&A Session**
- 17:00 Closing Remarks and Adjourn



Plenary Session
Frontiers in Thyroid Oncology
Saturday, March 19, 2022

07:30	Welcome and Introduction: S. Gulec
08:00-08:30	Molecular Pathology of Differentiated Thyroid Cancer: Y. Nikiforov
08:30-09:00	Mutational and Molecular Landscape of PDTC AND UDTc: M. Cabanillas
09:00-09:30	Perioperative Risk Stratification in Thyroid Cancer: M. Tuttle
09:30-10:00	Role for Molecular Testing in Perioperative Risk Stratification: Y. Nikiforov
10:00-10:30	<i>Break and Exhibits</i>
10:30-11:00	Science of Thyroidectomy in the Molecular Theranostics Paradigm: S. Gulec
11:00-11:30	Science of RAI Therapy in the Molecular Theranostics Paradigm: D. Van Nostrand
11:30-12:00	Panel Discussion- Q&A
12:00-13:00	<i>Lunch and exhibits</i>
13:00-13:30	Targeted Therapies For Aggressive Thyroid Cancer: M. Cabanillas
13:30-14:00	Redifferentiation Trials: J. Fagin
14:00-14:30	Active Surveillance for Malignant Nodules: M. Tuttle
14:30-15:00	<i>Break and Exhibits</i>
15:00-15:30	Ablative Approaches to Thyroid Nodules: E. Volpi
15:30-16:00	Clinical Molecular Testing Platforms: A. Kargi
16:00-17:00	Panel Discussion- Q&A
17:00	Closing Remarks and Adjourn

Organizing Committee

Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Anthony McGoron, PhD, Symposium Moderator

Professor of Biomedical Engineering and Associate Dean for Academic Affairs,
Florida International University College of Engineering and Computing
Executive Vice President, Miami Cancer Research Center, Miami, FL

Paul Perales-Villaruel, MD, Symposium Administrator

Chief Operating Officer
Miami Cancer Research Center, Miami, FL

Dahlia Mohammed, MPH, Symposium Planner

Vice President, Operations
Miami Cancer Research Center, Miami, FL



Miami Thyroid Oncology Symposium is organized by the Miami Cancer Research Center. Miami Cancer Research Center (MCRC) is a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support.



5th ANNUAL Miami Thyroid Oncology Symposium March 18-19, 2022

Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Dade County Medical Association and Miami Cancer Research Center. The Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians. DCMA designates this educational activity for a maximum of 16 AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Symposium Support

This symposium is supported by educational grants provided by the following industry partners

Platinum Sponsors

Jubilant Radiopharma

EISAI

Gold Sponsors

Lilly

Silver Sponsors

Thermo Fisher

RGS Healthcare

Ethicon

miamicancerresearch.org



March 18-19, 2022